Salim Wehbe, MD
NPI 1699714626 · Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) Physician · Sacramento, CA
Enrolled with Medicare as Practitioner - Other (physician) · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1699714626
- Entity type
- Individual
- Primary specialty
- Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) PhysicianAllopathic & Osteopathic Physicians
- Credential
- MD
- Sex
- Male
- Sole proprietor
- No
- License
- MD11929 (RI)
Specialties & taxonomies
- Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) PhysicianPrimary207VF0040XLicense A106873 (CA)
Allopathic & Osteopathic Physicians
Allopathic & Osteopathic Physicians
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure33% of score
20 yrs in NPPES registry
- Profile completeness33% of score
100% of core fields populated
- Practice footprint20% of score
1 documented practice location
- Open Payments transparency13% of score
Has Open Payments disclosures (2024)
Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our methodology.
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 16 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Estradiol | 342 | 207 |
| Estradiolbrand: Yuvafem | 208 | 79 |
| Trospium Chloride | 197 | 89 |
| Cephalexin | 106 | 70 |
| Mirabegronbrand: Myrbetriq | 98 | 35 |
| Methenamine Hippurate | 82 | 31 |
| Oxycodone Hcl | 57 | 53 |
| Solifenacin Succinate |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$80 across 1 record (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2006-06-05
- Last updated
- 2021-12-21
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.